Federal pricing agreement cuts Lilly's direct-to-consumer Zepbound prices

Eli Lilly's self-pay prices for Zepbound (tirzepatide) have been restructured following the November 2025 pricing agreement between the company and the Trump administration, and the federal TrumpRx site now lists Zepbound cash prices. A consumer pricing guide that tracks the programs reports that TrumpRx.gov lists Zepbound starting at $299 a month, with the listing handing shoppers off to LillyDirect, Lilly's direct-to-patient platform, to place the order ^[1].

The specific terms of the November 2025 agreement itself — what Lilly promised, and what it received in return — are not described in the source material available for this story, so those details are not yet confirmed here. What is documented is the pricing that followed: the guide cites an Eli Lilly pricing announcement in December 2025 and Self Pay Journey Program terms revised in March 2026 ^[1].

What the prices actually look like

The $299 figure applies only to the 2.5 mg starting dose. The published ladder is $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg — compared with an original list price of roughly $1,087 ^[1].

The $449 tier carries a condition. It holds only if the prescription is refilled within 45 days. Miss that window and a single fill runs $499 for 7.5 mg, or $699 for 10 mg, 12.5 mg and 15 mg, plus taxes and fees. The $299 and $399 tiers are unchanged by the 45-day rule ^[1]. A one-month supply is defined as 28 days — four vials or one KwikPen — and the pricing applies to both forms ^[1].

Because 2.5 mg is a starting dose rather than a long-term maintenance dose under the FDA label, the guide estimates a real-world cash average closer to $430 a month for someone who titrates up on schedule, or about $5,188 over 12 months. Staying at 5 mg for the year works out to roughly $4,688 ^[1]. The guide also flags an older, widely circulated $350 figure as an outdated blended number ^[1].

TrumpRx is described as a directory rather than a pharmacy. The site launched February 5, 2026, is built around most-favored-nation pricing — tying U.S. prices to what other wealthy countries pay — and at launch featured medicines from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[1]. For Zepbound, ordering through TrumpRx gets the same product at the same price as going directly to LillyDirect, which also added Walmart pharmacy pickup in late 2025 ^[1].

Why it matters for patients

For people paying cash, the practical takeaway is that the headline number and the bill are different things. The advertised $299 covers one dose level; most of the year's cost sits in the $399 to $449 range, and the 45-day refill condition can add $50 to $250 to a single higher-dose fill ^[1].

Cash pricing is also not automatically the cheapest route. With commercial insurance and a savings card, the guide says costs can drop to as little as $25 a month — though government insurance cannot use the savings card ^[1].

There is a compounding angle, too. TrumpRx and LillyDirect supply brand-name, FDA-approved tirzepatide. Compounded tirzepatide is described as a separate, non-FDA-approved category that TrumpRx does not offer ^[1]. As branded cash prices fall, the gap that drove some patients toward compounded versions narrows — but the two categories remain regulated differently.

A prescription is still required. TrumpRx does not replace a clinician, and LillyDirect expects a valid, on-label prescription. On-label eligibility generally means a BMI of 30 or higher, or 27 or higher with a weight-related condition ^[1].

What happens next

A Medicare GLP-1 Bridge program is scheduled to start July 1, 2026, offering eligible Part D members a 30-day supply for $50, with prior authorization required. As described, it covers the KwikPen only — not vials or the single-dose pen — and the request is submitted by the patient's own prescriber ^[1].

Whether the self-pay tiers hold at these levels is not yet known. The source notes that prices and program rules change quickly and that Lilly's self-pay terms have already been revised once, in March 2026 ^[1].